The global market for Drugs for Short Bowel Syndrome was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Drugs for Short Bowel Syndrome, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Drugs for Short Bowel Syndrome by region & country, by Type, and by Application.

The Drugs for Short Bowel Syndrome market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Short Bowel Syndrome.

Market Segmentation

Scope of Drugs for Short Bowel Syndrome - Market Report

Report Metric	Details
Report Name	Drugs for Short Bowel Syndrome - Market
CAGR	5%
Segment by Type:	GLP-2 Growth Hormone Glutamine Other
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Ardelyx, Emmaus Life Sciences, GLyPharma Therapeutic, Merck, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio & Company, Takeda, Zealand Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Drugs for Short Bowel Syndrome manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Drugs for Short Bowel Syndrome in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Drugs for Short Bowel Syndrome in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Drugs for Short Bowel Syndrome - Market report?

Ans: The main players in the Drugs for Short Bowel Syndrome - Market are Ardelyx, Emmaus Life Sciences, GLyPharma Therapeutic, Merck, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio & Company, Takeda, Zealand Pharma

What are the Application segmentation covered in the Drugs for Short Bowel Syndrome - Market report?

Ans: The Applications covered in the Drugs for Short Bowel Syndrome - Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Drugs for Short Bowel Syndrome - Market report?

Ans: The Types covered in the Drugs for Short Bowel Syndrome - Market report are GLP-2, Growth Hormone, Glutamine, Other

1 Market Overview

1.1 Drugs for Short Bowel Syndrome Product Introduction

1.2 Global Drugs for Short Bowel Syndrome Market Size Forecast

1.3 Drugs for Short Bowel Syndrome Market Trends & Drivers

1.3.1 Drugs for Short Bowel Syndrome Industry Trends

1.3.2 Drugs for Short Bowel Syndrome Market Drivers & Opportunity

1.3.3 Drugs for Short Bowel Syndrome Market Challenges

1.3.4 Drugs for Short Bowel Syndrome Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Drugs for Short Bowel Syndrome Players Revenue Ranking (2023)

2.2 Global Drugs for Short Bowel Syndrome Revenue by Company (2019-2024)

2.3 Key Companies Drugs for Short Bowel Syndrome Manufacturing Base Distribution and Headquarters

2.4 Key Companies Drugs for Short Bowel Syndrome Product Offered

2.5 Key Companies Time to Begin Mass Production of Drugs for Short Bowel Syndrome

2.6 Drugs for Short Bowel Syndrome Market Competitive Analysis

2.6.1 Drugs for Short Bowel Syndrome Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Drugs for Short Bowel Syndrome Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Short Bowel Syndrome as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 GLP-2

3.1.2 Growth Hormone

3.1.3 Glutamine

3.1.4 Other

3.2 Global Drugs for Short Bowel Syndrome Sales Value by Type

3.2.1 Global Drugs for Short Bowel Syndrome Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Drugs for Short Bowel Syndrome Sales Value, by Type (2019-2030)

3.2.3 Global Drugs for Short Bowel Syndrome Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital Pharmacies

4.1.2 Retail Pharmacies

4.1.3 Online Pharmacies

4.2 Global Drugs for Short Bowel Syndrome Sales Value by Application

4.2.1 Global Drugs for Short Bowel Syndrome Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Drugs for Short Bowel Syndrome Sales Value, by Application (2019-2030)

4.2.3 Global Drugs for Short Bowel Syndrome Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Drugs for Short Bowel Syndrome Sales Value by Region

5.1.1 Global Drugs for Short Bowel Syndrome Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Drugs for Short Bowel Syndrome Sales Value by Region (2019-2024)

5.1.3 Global Drugs for Short Bowel Syndrome Sales Value by Region (2025-2030)

5.1.4 Global Drugs for Short Bowel Syndrome Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Drugs for Short Bowel Syndrome Sales Value, 2019-2030

5.2.2 North America Drugs for Short Bowel Syndrome Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Drugs for Short Bowel Syndrome Sales Value, 2019-2030

5.3.2 Europe Drugs for Short Bowel Syndrome Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Drugs for Short Bowel Syndrome Sales Value, 2019-2030

5.4.2 Asia Pacific Drugs for Short Bowel Syndrome Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Drugs for Short Bowel Syndrome Sales Value, 2019-2030

5.5.2 South America Drugs for Short Bowel Syndrome Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Drugs for Short Bowel Syndrome Sales Value, 2019-2030

5.6.2 Middle East & Africa Drugs for Short Bowel Syndrome Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Drugs for Short Bowel Syndrome Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Drugs for Short Bowel Syndrome Sales Value

6.3 United States

6.3.1 United States Drugs for Short Bowel Syndrome Sales Value, 2019-2030

6.3.2 United States Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Drugs for Short Bowel Syndrome Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Drugs for Short Bowel Syndrome Sales Value, 2019-2030

6.4.2 Europe Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Drugs for Short Bowel Syndrome Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Drugs for Short Bowel Syndrome Sales Value, 2019-2030

6.5.2 China Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

6.5.3 China Drugs for Short Bowel Syndrome Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Drugs for Short Bowel Syndrome Sales Value, 2019-2030

6.6.2 Japan Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Drugs for Short Bowel Syndrome Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Drugs for Short Bowel Syndrome Sales Value, 2019-2030

6.7.2 South Korea Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Drugs for Short Bowel Syndrome Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Drugs for Short Bowel Syndrome Sales Value, 2019-2030

6.8.2 Southeast Asia Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Drugs for Short Bowel Syndrome Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Drugs for Short Bowel Syndrome Sales Value, 2019-2030

6.9.2 India Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

6.9.3 India Drugs for Short Bowel Syndrome Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Ardelyx

7.1.1 Ardelyx Profile

7.1.2 Ardelyx Main Business

7.1.3 Ardelyx Drugs for Short Bowel Syndrome Products, Services and Solutions

7.1.4 Ardelyx Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2019-2024)

7.1.5 Ardelyx Recent Developments

7.2 Emmaus Life Sciences

7.2.1 Emmaus Life Sciences Profile

7.2.2 Emmaus Life Sciences Main Business

7.2.3 Emmaus Life Sciences Drugs for Short Bowel Syndrome Products, Services and Solutions

7.2.4 Emmaus Life Sciences Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2019-2024)

7.2.5 Emmaus Life Sciences Recent Developments

7.3 GLyPharma Therapeutic

7.3.1 GLyPharma Therapeutic Profile

7.3.2 GLyPharma Therapeutic Main Business

7.3.3 GLyPharma Therapeutic Drugs for Short Bowel Syndrome Products, Services and Solutions

7.3.4 GLyPharma Therapeutic Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2019-2024)

7.3.5 Merck Recent Developments

7.4 Merck

7.4.1 Merck Profile

7.4.2 Merck Main Business

7.4.3 Merck Drugs for Short Bowel Syndrome Products, Services and Solutions

7.4.4 Merck Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2019-2024)

7.4.5 Merck Recent Developments

7.5 Naia Pharmaceuticals

7.5.1 Naia Pharmaceuticals Profile

7.5.2 Naia Pharmaceuticals Main Business

7.5.3 Naia Pharmaceuticals Drugs for Short Bowel Syndrome Products, Services and Solutions

7.5.4 Naia Pharmaceuticals Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2019-2024)

7.5.5 Naia Pharmaceuticals Recent Developments

7.6 Nutrinia

7.6.1 Nutrinia Profile

7.6.2 Nutrinia Main Business

7.6.3 Nutrinia Drugs for Short Bowel Syndrome Products, Services and Solutions

7.6.4 Nutrinia Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2019-2024)

7.6.5 Nutrinia Recent Developments

7.7 OxThera

7.7.1 OxThera Profile

7.7.2 OxThera Main Business

7.7.3 OxThera Drugs for Short Bowel Syndrome Products, Services and Solutions

7.7.4 OxThera Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2019-2024)

7.7.5 OxThera Recent Developments

7.8 Sancilio & Company

7.8.1 Sancilio & Company Profile

7.8.2 Sancilio & Company Main Business

7.8.3 Sancilio & Company Drugs for Short Bowel Syndrome Products, Services and Solutions

7.8.4 Sancilio & Company Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2019-2024)

7.8.5 Sancilio & Company Recent Developments

7.9 Takeda

7.9.1 Takeda Profile

7.9.2 Takeda Main Business

7.9.3 Takeda Drugs for Short Bowel Syndrome Products, Services and Solutions

7.9.4 Takeda Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2019-2024)

7.9.5 Takeda Recent Developments

7.10 Zealand Pharma

7.10.1 Zealand Pharma Profile

7.10.2 Zealand Pharma Main Business

7.10.3 Zealand Pharma Drugs for Short Bowel Syndrome Products, Services and Solutions

7.10.4 Zealand Pharma Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2019-2024)

7.10.5 Zealand Pharma Recent Developments

8 Industry Chain Analysis

8.1 Drugs for Short Bowel Syndrome Industrial Chain

8.2 Drugs for Short Bowel Syndrome Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Drugs for Short Bowel Syndrome Sales Model

8.5.2 Sales Channel

8.5.3 Drugs for Short Bowel Syndrome Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Ardelyx Inc

Emmaus Life Sciences

GLyPharma Therapeutic

List of Tables

Table 1. Drugs for Short Bowel Syndrome Market Trends

Table 2. Drugs for Short Bowel Syndrome Market Drivers & Opportunity

Table 3. Drugs for Short Bowel Syndrome Market Challenges

Table 4. Drugs for Short Bowel Syndrome Market Restraints

Table 5. Global Drugs for Short Bowel Syndrome Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Drugs for Short Bowel Syndrome Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Drugs for Short Bowel Syndrome Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Drugs for Short Bowel Syndrome Product Type

Table 9. Key Companies Time to Begin Mass Production of Drugs for Short Bowel Syndrome

Table 10. Global Drugs for Short Bowel Syndrome Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Short Bowel Syndrome as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Drugs for Short Bowel Syndrome Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Drugs for Short Bowel Syndrome Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Drugs for Short Bowel Syndrome Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Drugs for Short Bowel Syndrome Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Drugs for Short Bowel Syndrome Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Drugs for Short Bowel Syndrome Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Drugs for Short Bowel Syndrome Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Drugs for Short Bowel Syndrome Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Drugs for Short Bowel Syndrome Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Drugs for Short Bowel Syndrome Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Drugs for Short Bowel Syndrome Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Drugs for Short Bowel Syndrome Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Drugs for Short Bowel Syndrome Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Drugs for Short Bowel Syndrome Sales Value by Region (2019-2024) & (%)

Table 27. Global Drugs for Short Bowel Syndrome Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Drugs for Short Bowel Syndrome Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Drugs for Short Bowel Syndrome Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Drugs for Short Bowel Syndrome Sales Value, (2025-2030) & (US$ Million)

Table 31. Ardelyx Basic Information List

Table 32. Ardelyx Description and Business Overview

Table 33. Ardelyx Drugs for Short Bowel Syndrome Products, Services and Solutions

Table 34. Revenue (US$ Million) in Drugs for Short Bowel Syndrome Business of Ardelyx (2019-2024)

Table 35. Ardelyx Recent Developments

Table 36. Emmaus Life Sciences Basic Information List

Table 37. Emmaus Life Sciences Description and Business Overview

Table 38. Emmaus Life Sciences Drugs for Short Bowel Syndrome Products, Services and Solutions

Table 39. Revenue (US$ Million) in Drugs for Short Bowel Syndrome Business of Emmaus Life Sciences (2019-2024)

Table 40. Emmaus Life Sciences Recent Developments

Table 41. GLyPharma Therapeutic Basic Information List

Table 42. GLyPharma Therapeutic Description and Business Overview

Table 43. GLyPharma Therapeutic Drugs for Short Bowel Syndrome Products, Services and Solutions

Table 44. Revenue (US$ Million) in Drugs for Short Bowel Syndrome Business of GLyPharma Therapeutic (2019-2024)

Table 45. GLyPharma Therapeutic Recent Developments

Table 46. Merck Basic Information List

Table 47. Merck Description and Business Overview

Table 48. Merck Drugs for Short Bowel Syndrome Products, Services and Solutions

Table 49. Revenue (US$ Million) in Drugs for Short Bowel Syndrome Business of Merck (2019-2024)

Table 50. Merck Recent Developments

Table 51. Naia Pharmaceuticals Basic Information List

Table 52. Naia Pharmaceuticals Description and Business Overview

Table 53. Naia Pharmaceuticals Drugs for Short Bowel Syndrome Products, Services and Solutions

Table 54. Revenue (US$ Million) in Drugs for Short Bowel Syndrome Business of Naia Pharmaceuticals (2019-2024)

Table 55. Naia Pharmaceuticals Recent Developments

Table 56. Nutrinia Basic Information List

Table 57. Nutrinia Description and Business Overview

Table 58. Nutrinia Drugs for Short Bowel Syndrome Products, Services and Solutions

Table 59. Revenue (US$ Million) in Drugs for Short Bowel Syndrome Business of Nutrinia (2019-2024)

Table 60. Nutrinia Recent Developments

Table 61. OxThera Basic Information List

Table 62. OxThera Description and Business Overview

Table 63. OxThera Drugs for Short Bowel Syndrome Products, Services and Solutions

Table 64. Revenue (US$ Million) in Drugs for Short Bowel Syndrome Business of OxThera (2019-2024)

Table 65. OxThera Recent Developments

Table 66. Sancilio & Company Basic Information List

Table 67. Sancilio & Company Description and Business Overview

Table 68. Sancilio & Company Drugs for Short Bowel Syndrome Products, Services and Solutions

Table 69. Revenue (US$ Million) in Drugs for Short Bowel Syndrome Business of Sancilio & Company (2019-2024)

Table 70. Sancilio & Company Recent Developments

Table 71. Takeda Basic Information List

Table 72. Takeda Description and Business Overview

Table 73. Takeda Drugs for Short Bowel Syndrome Products, Services and Solutions

Table 74. Revenue (US$ Million) in Drugs for Short Bowel Syndrome Business of Takeda (2019-2024)

Table 75. Takeda Recent Developments

Table 76. Zealand Pharma Basic Information List

Table 77. Zealand Pharma Description and Business Overview

Table 78. Zealand Pharma Drugs for Short Bowel Syndrome Products, Services and Solutions

Table 79. Revenue (US$ Million) in Drugs for Short Bowel Syndrome Business of Zealand Pharma (2019-2024)

Table 80. Zealand Pharma Recent Developments

Table 81. Key Raw Materials Lists

Table 82. Raw Materials Key Suppliers Lists

Table 83. Drugs for Short Bowel Syndrome Downstream Customers

Table 84. Drugs for Short Bowel Syndrome Distributors List

Table 85. Research Programs/Design for This Report

Table 86. Key Data Information from Secondary Sources

Table 87. Key Data Information from Primary Sources

Table 88. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Drugs for Short Bowel Syndrome Product Picture

Figure 2. Global Drugs for Short Bowel Syndrome Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Drugs for Short Bowel Syndrome Sales Value (2019-2030) & (US$ Million)

Figure 4. Drugs for Short Bowel Syndrome Report Years Considered

Figure 5. Global Drugs for Short Bowel Syndrome Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Drugs for Short Bowel Syndrome Revenue in 2023

Figure 7. Drugs for Short Bowel Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. GLP-2 Picture

Figure 9. Growth Hormone Picture

Figure 10. Glutamine Picture

Figure 11. Other Picture

Figure 12. Global Drugs for Short Bowel Syndrome Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 13. Global Drugs for Short Bowel Syndrome Sales Value Market Share by Type, 2023 & 2030

Figure 14. Product Picture of Hospital Pharmacies

Figure 15. Product Picture of Retail Pharmacies

Figure 16. Product Picture of Online Pharmacies

Figure 17. Global Drugs for Short Bowel Syndrome Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global Drugs for Short Bowel Syndrome Sales Value Market Share by Application, 2023 & 2030

Figure 19. North America Drugs for Short Bowel Syndrome Sales Value (2019-2030) & (US$ Million)

Figure 20. North America Drugs for Short Bowel Syndrome Sales Value by Country (%), 2023 VS 2030

Figure 21. Europe Drugs for Short Bowel Syndrome Sales Value (2019-2030) & (US$ Million)

Figure 22. Europe Drugs for Short Bowel Syndrome Sales Value by Country (%), 2023 VS 2030

Figure 23. Asia Pacific Drugs for Short Bowel Syndrome Sales Value (2019-2030) & (US$ Million)

Figure 24. Asia Pacific Drugs for Short Bowel Syndrome Sales Value by Country (%), 2023 VS 2030

Figure 25. South America Drugs for Short Bowel Syndrome Sales Value (2019-2030) & (US$ Million)

Figure 26. South America Drugs for Short Bowel Syndrome Sales Value by Country (%), 2023 VS 2030

Figure 27. Middle East & Africa Drugs for Short Bowel Syndrome Sales Value (2019-2030) & (US$ Million)

Figure 28. Middle East & Africa Drugs for Short Bowel Syndrome Sales Value by Country (%), 2023 VS 2030

Figure 29. Key Countries/Regions Drugs for Short Bowel Syndrome Sales Value (%), (2019-2030)

Figure 30. United States Drugs for Short Bowel Syndrome Sales Value, (2019-2030) & (US$ Million)

Figure 31. United States Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

Figure 32. United States Drugs for Short Bowel Syndrome Sales Value by Application (%), 2023 VS 2030

Figure 33. Europe Drugs for Short Bowel Syndrome Sales Value, (2019-2030) & (US$ Million)

Figure 34. Europe Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

Figure 35. Europe Drugs for Short Bowel Syndrome Sales Value by Application (%), 2023 VS 2030

Figure 36. China Drugs for Short Bowel Syndrome Sales Value, (2019-2030) & (US$ Million)

Figure 37. China Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

Figure 38. China Drugs for Short Bowel Syndrome Sales Value by Application (%), 2023 VS 2030

Figure 39. Japan Drugs for Short Bowel Syndrome Sales Value, (2019-2030) & (US$ Million)

Figure 40. Japan Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

Figure 41. Japan Drugs for Short Bowel Syndrome Sales Value by Application (%), 2023 VS 2030

Figure 42. South Korea Drugs for Short Bowel Syndrome Sales Value, (2019-2030) & (US$ Million)

Figure 43. South Korea Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

Figure 44. South Korea Drugs for Short Bowel Syndrome Sales Value by Application (%), 2023 VS 2030

Figure 45. Southeast Asia Drugs for Short Bowel Syndrome Sales Value, (2019-2030) & (US$ Million)

Figure 46. Southeast Asia Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

Figure 47. Southeast Asia Drugs for Short Bowel Syndrome Sales Value by Application (%), 2023 VS 2030

Figure 48. India Drugs for Short Bowel Syndrome Sales Value, (2019-2030) & (US$ Million)

Figure 49. India Drugs for Short Bowel Syndrome Sales Value by Type (%), 2023 VS 2030

Figure 50. India Drugs for Short Bowel Syndrome Sales Value by Application (%), 2023 VS 2030

Figure 51. Drugs for Short Bowel Syndrome Industrial Chain

Figure 52. Drugs for Short Bowel Syndrome Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions